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Abstract.  Brexit has been a hot topic of discussions since the referendum held in June 23 2016; the long and 
difficult negotiations and multiple delays of the Brexit have caused uncertainty and confusion in pharmaceutical 
industry in both UK and EU. As EU pharmaceutical companies have been part of UK pharmaceutical market for 
decades and makes considerable contribution to UK`s health system it is important to acknowledge what the Brexit 
might bring to the industry and how the company marketing strategies should be aligned to cope with the consequences 
caused by Brexit.  
Purpose of the article: The purpose of the research is to assess the influence of Brexit on EU and UK 
pharmaceutical markets and industry in order to acknowledge potential risks, challenges for conducting marketing 
activities in UK pharmaceutical market after Brexit. The findings of this article could later be used by pharmaceutical 
industry professionals to better understand the Brexit influence on pharmaceutical industry and align their marketing 
strategy. 
Objective: To assess the possible consequences of Brexit on UK and EU pharmaceutical markets and industry. 
Methodology/methods: In order to attain the goal and objectives, the following quantitative and qualitative 
methods were used: meta and content analyses, analysis of the most recent scientific and professional literature 
available and in-depth interviews of industry experts. The study is based on scientific papers published by foreign 
scholars, general and special literature, periodicals, governmental and industry reports. 
Findings: the research outlined the challenges that pharmaceutical industry is facing due to Brexit process; it also 
outlines the possible future challenges that industry might face in the future and outlines possible solutions that can 
be adapted in practice. 
Keywords: Pharmaceutical Industry, EU Pharmaceutical Market, Brexit, Pharmaceutical product availability. 
JEL code: M31 
Introduction 
As potential Brexit has brought confusion and uncertainty to the pharmaceutical industry in EU it is important to 
acknowledge the main issues that pharmaceutical companies willing to operate in UK will have to face when Brexit 
will take place. As pharmaceutical industry is one of the main industries in Latvia the research is focused on finding 
possible solutions and possible marketing strategies for companies that are willing to conduct business in UK 
pharmaceutical market. 
The objective of the research is to study and assess the possible consequences and influence of UK leaving the 
EU on pharmaceutical industry in both EU and UK as well the possible challenges and opportunities that might arise 
after Brexit. 
In order to achieve this objective, the research was based on the study of meta and content analyses, analysis of 
the most recent scientific and professional literature available, in-depth interviews with directors of Latvian, UK and 
Ireland Pharmaceutical companies and scientific literature databases were used as information sources. 
Research shows that since Brexit vote has taken place it has caused a significant influence on UK pharmaceutical 
industry resulting in reduced development and postponed investments caused by uncertainty of possible Brexit 
scenarios. Both EU and UK`s pharmaceutical companies will have to adapt their marketing and regulatory strategies 
in order to align with UK leaving the joint EU registration procedures. By outlining the major challenges 
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pharmaceutical industry could face the research authors hope the industry can adapt timely their strategies to better 
coupe with these challenges and reduce Brexit negative consequences. 
Literature Review 
Publications of UK Medicines and Healthcare products Regulatory Agency, UK Parliament House of Commons 
and European Medicines Agency were used to reflect current political and regulatory processes concerning 
pharmaceutical industry. 
Industry reports from Marketline and OECD were used to analyze the pharmaceutical market tends in EU and UK. 
Articles from Journal of Pharmaceutical Policy and Practice, Forensic Science International, Expert Opinion on 
Drug Discovery, Medical Writing, The Pharmaceutical Journal, British Journal of Pharmacy and Journal of 
Pharmaceutical Policy and Practice, OECD Economic Policy Papers, Journal of Economic Perspectives and other 
related sources were used as information sources. 
Multiple interview of experts in pharmaceutical field were conducted, including head of regulatory department of 
a Latvian pharmaceutical producer, managing director of a pharmaceutical distribution company in Ireland, business 
development and clinical affairs director of a pharmaceutical distribution company in UK and a business development 
director of a UK pharmaceutical producer. 
The causes of Brexit taking place, it`s current influence on the UK`s economy, investments and pharmaceutical 
industry have been assessed by multiple authors, as well as possible scenarios of post-Brexit development in both EU 
and UK  have been outlined. It has been noted that possibility of Brexit has slowed down the UK`s economic growth 
and caused uncertainty among investors and industry; whereas there`s considerably less research been done on Brexit 
potential consequences on EU industries. 
1.Brexit development and current influence 
Brexit started as an innocent idea by UK`s Prime Minister at that time David Cameron in early 2013 (January 23) 
in a speech at Bloomberg outlining the idea of UK resetting its role within EU. The innocent idea later turned into a 
dangerous flirt with the public that eventually led to a referendum on UK`s possible withdrawal from EU (June 23 
2016) (House of Commons, 2019). 
The referendum resulted in tight vote with 51.9% voting to exit EU. The positive vote came as a negative surprise 
to UK and the global community – the voting outcome was later explained by social inequality caused by the 
globalization (Pettifor, 2016; Clarke, Goodwin and Whiteley, 2017; Colantone and Stanig, 2018). UK proceeded with 
its goal to exit EU and triggered the Article 50 of the Treaty on European Union in March 29 2017, thus formally 
starting the Brexit procedure. 
Year 2018 continued with intense negotiations between EU and UK on the Brexit terms; in parallel the public 
started to prepare for a no-deal Brexit.  
So far the possible Brexit and multiple delays of it taking place has brought concerns and uncertainty of UK`s 
economies future and development – as per OECD reviews the chaotic Brexit development has impacted consumption, 
investments and the economic activity in UK (OECD, 2017).  
Due to uncertainty of Brexit, consumer and investment sentiment has slowed down since 2016 which impacted 
the economic growth rate of the UK – economic growth, which averaged 2.45% during 2013–2015, slowed down to 
an average of 1.67% during 2016–2018 (MarketLine, 2019). Some of researches even suggest that the uncertainty 
caused by Brexit is one of the major causes of the development slow down (Steinberg, 2019). 
Brexit has also affected the development of the UK Pharmaceuticals market, and the future looks increasingly 
uncertain. The first major blow to the UK`s pharmaceutical market came within a year after the referendum and the 
decision to proceed with Brexit when the European Medicines Agency announced its departure from the UK and 
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relocation to Amsterdam (MarketLine, 2019). This was a significant loss to UK`s pharmaceutical industry, which over 
the years had developed a close cooperation between the EMA and the UK regulatory body (MHRA). Prior the Brexit 
referendum, due to its regulatory leadership, world-leading research base and well integrated National Health System, 
UK was the preferred option for European drug manufacturers who were seeking to register their pharmaceutical 
product in the European Market. The UK`s leading role as preferred platform for pharmaceutical product registration 
boosted its economy and health system with investments, taxes, intellectual property filings and UK citizens gaining 
access to innovative drugs much faster than in other healthcare systems within Europe.  
It has been noted that since 2016, Brexit has had a significant effect on investment caused by legislative and 
regulatory uncertainty that has resulted in the pharmaceutical industry being precautions to further investments in UK 
(MarketLine, 2019). Studies have outlined that since Brexit vote not only the investments in UK have reduced (by 
11%), but also have had negative effect on UK industry productivity as it`s top management has to focus their attention 
to post-Brexit scenario planning (Bloom et al., 2019). 
Furthermore, authors of this study noticed some similarities in the stock value development of two major 
pharmaceutical producers in UK (GlaxoSmithKline and AstraZeneca) after the Brexit referendum taking place and 
being followed by inconvenient development of the Brexit process and multiple delays in UK actually leaving the EU 
(as shown in Figure 1 below). Although direct correlation between Brexit discussions and stock market value changes 
have not been approved the similarity in stock value trends could be explained by shifts of British Pound value 
(Breinlich et al., 2018). 
 
Source: authors’ calculation based on (NASDAQ Exchange, 2019) 
Fig. 1 GlaxoSmithKline and AstraZeneca stock value changes (01.05.2016. – 10.25.2019.) 
 
2.EU and UK Pharmaceutical market overview outlining future business opportunities 
As per Marketline report of Europe pharmaceutical industry in 2019, the European pharmaceuticals market grew by 
3.1% in 2018 to reach a value of $286.9 billion. The compound annual growth rate of the market in the period 2014–
18 was 2.6%. In comparison the Marketline report of UK`s pharmaceutical industry in 2019, the pharmaceuticals 
market in UK grew by 3.9% in 2018 to reach a value of $26.9 billion. The compound annual growth rate of the market 
in the period 2014–18 was 0.6% (as shown in Table 1 below). 
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Europe and UK pharmaceuticals market value: $ billion, 2014–18 
Year 
Europe UK 
€ billion Growth, % € billion Growth, % 
2014 219.6   26.3  
2015 225.1 2.5% 27.0 2.7% 
2016 228.2 1.4% 25.1 -7.0% 
2017 235.6 3.2% 25.9 3.2% 
2018 243.0 3.1% 26.9 3.9% 
CAGR: 2014–18 2.6% 0.6% 
Source: authors’ calculation based on (MarketLine, 2019) 
The reports also predicts that in 2023, the European pharmaceuticals market is forecast to have a value of $344.5 
billion, an increase of 20.1% since 2018. The compound annual growth rate of the market in the period 2018–23 is 
predicted to be 3.7%. In comparison the UK`s pharmaceuticals market is forecasted to have a value of $32.1 billion 
in Year 2023, an increase of 19.3% since 2018. The compound annual growth rate of the market in the period 2018–
23 is predicted to be 3.6% (as shown in Table 2 below). 
Table 2  
Europe and UK pharmaceuticals market value forecast: $ billion, 2018–23 
Year 
Europe UK 
€ billion Growth, % € billion Growth, % 
2018 286.9 3.1% 26.9 3.9% 
2019 296.5 3.3% 27.8 3.3% 
2020 306.9 3.5% 28.8 3.6% 
2021 318.3 3.7% 29.8 3.5% 
2022 330.8 3.9% 30.9 3.7% 
2023 344.5 4.1% 32.1 4.0% 
CAGR: 2018–23 3.7% 3.6% 
Source: authors’ calculation based (MarketLine, 2019) 
As noted by OECD report on international trade 2019, UK is historically importing pharmaceutical products from 
EU27 in a greater value than it is exporting to these markets. Balance of pharmaceutical import and export from UK 
to EU27 balances in between of 9,7$ billion and 10,5$ billion in favor of EU27 during Years 2014-2018 (as shown in 
Figure 2 below). 
 
Source: authors’ calculation based on (OECD, 2019) 
Fig. 2 Import, export values and balance of UK pharmaceutical products to EU27 
$27,413 $25,802 $25,406 $26,179 $23,711 
$17,719 
$15,311 $15,603 $15,837 $13,966 





















Market data shows that while EU pharmaceutical market has a steady development trend, UK has had a significant 
decrease (-7%) on pharmaceutical market in Year 2016 that could be linked to inconvenience caused by possible 
Brexit. The compound annual growth rate in next 4 Years for both UK and EU pharmaceutical markets is expected to 
be similar (3.6% - 3.7%) with EU having slightly better expectations. The decline and weakened growth in UK market 
and industry has been noted by multiple reports and linked to uncertainty of UK future after Brexit taking place (OECD, 
2016).  
The pharmaceutical product import and export trends in UK market shows that UK is quite dependent on product 
supplies from EU. The possible Brexit brings opportunities for both – UK  companies to take greater domestic market 
share, thus reducing import value from EU; and for EU pharmaceutical producers Brexit brings opportunities for those 
who are flexible enough to align with complex and unpredictable UK`s post-Brexit market to bypass companies that 
will no longer supply their products to UK. 
Also, it has been outlined by multiple researches that Brexit will cause a slower growth in UK that it would have 
been if it remained in EU (Sampson, 2017). The trade relations and environment is expected to worsen after Brexit 
taking place would cause negative effects for both UK and EU and also other major countries worldwide; a trade 
agreement between EU and UK would reduce the negative consequences of Brexit (Brakman, Garretsen and Kohl, 
2017),  (Morley, 2019). 
Although most of the reviewed studies predict that Brexit would bring loss to the UK`s economy, it is stipulated 
that Brexit could bring some advantages to UK if the trade policies and negotiations are played out smart, especially 
in the fields where UK has high imports of intermediate products and low exports of final goods to the EU, by 
increasing the local value of the final goods (Felbermayr, 2019).  
As described by studies focusing on turbulent market situations, the changing market situation, as it is with Brexit, 
might draw concerns to enterprises asset quality and profitability, thus pushing enterprises to optimize their asset and 
liability structure in order to reduce financial risks and remain profitable (Saksonova, 2013). 
Also, in order to reduce the influence on Brexit caused negative risks the enterprises should review their 
development and marketing strategies (Saksonova and Solovjova, 2012) and enterprises might favor merging and 
acquiring strategies even more to increase the enterprises competitiveness and industry development (Saksonova and 
Kantane, 2017). 
Thus the Authors see a probability that due to Brexit the UK pharmaceutical companies may tend to choosing the 
path of merging and acquiring to enhance their competitiveness in the UK and EU market. 
3.Regulatory differences of Pharmaceutical product registration (EU vs. UK) and their influence 
 on pharmaceutical market development 
Pharmaceutical product registration is a mandatory and complex regulatory process that is required prior products 
can be introduced in corresponding markets. Same as with uncertainties with economics development due to possible 
Brexit the regulatory processes faces similar concerns. Although no radical changes in the EU policies have been 
made so far, it is expected that EU policies could become less liberal in the future (De Ville and Siles-Brügge, 2019). 
In parallel, it is noted by regulatory experts that EU and UK producers are already facing with multiple difficulties 
and foresee possible regulatory trends and challenges in post-Brexit scenario. 
It is expected that pharmaceutical product registrations for UK market that have been submitted within EU joint 
registration procedures will automatically be transferred to UK`s National registration procedure, thus the registration 
finalization of the product in UK becomes less predictable. 
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After Brexit taking place the joint EU procedures where UK is acting as Reporting Member State (RMS) the 
pharmaceutical producers will have to choose different RMS country, thus increasing the workload of National 
Competent Authorities Regulatory expert workload in such member states. 
The National registration procedure timelines in UK are quite similar to the ones set in the EU joint registration 
procedures, but there is doubt that the timelines will remain the same after Brexit as MHRA experts will have to assess 
the registration documentation independently, without direct assistance from other EU competent authority experts as 
it would be during joint EU registration procedures. Furthermore, due to higher input from its regulatory experts, 
MHRE is expected to face need in increasing its regulatory staff. 
Regulatory experts outlined the advantage of National registration procedure (in comparison to EU joint 
registration procedures) by noting that assessment doesn`t have to be aligned and approved by other Concerned 
Member States (CMS). Nonetheless such approach requires additional effort for both the National Competent 
authority and pharmaceutical producer as in general it runs as an independent registration procedure that requires 
almost the same effort as the joint registration procedure. 
As disclosed by regulatory experts, due to uncertainty with the Brexit timelines (as it has been postponed multiple 
times), there has been situations where a joint registration procedure RMS would reject adding UK as a CMS if the 
joint procedure would end after the initially set Brexit deadline, thus confusing pharmaceutical producers on choosing 
the right strategy for pharmaceutical product registration in UK. Also, there have been situations when MHRA would 
reject the pharmaceutical product registration submission if the product has an ongoing joint registration procedure in 
EU – the pharmaceutical producer would them be suggested to include UK as CMS in the joint procedure in despite 
of the previously mentioned concerns set by the RMS. 
Majority of experts during their interviews noted that pharmaceutical product applications that have been 
submitted for National registration in UK in Year 2019 so far have considerably slower progress if compared to EU 
joint registration procedure and the feedback from MHRE has been slow despite the proactive communication and 
initiative from the submitter’s side. They also noted that in some cases while the application of pharmaceutical product 
registration has been submitted in parallel in both EU joint and UK National registration procedures, the EU joint 
procedure has been finalized  first while the UK national procedure still continues, thus showing an example that joint 
registration procedures can run more smoothly and convenient. 
After the Brexit taking place and having no alternative joint registration procedure with EU, the pharmaceutical 
producers will have no other option than to submit the pharmaceutical products for registration in EU and UK 
independently, thus running two registration procedures instead of one joint procedure. This also increases the 
workload for both the producer and the MHRA.  
From a pharmaceutical producers point of view the National registration fees in UK are higher (although 
insignificantly) if compared with applied fees for EU joint registration procedures (as shown in Table 3 below). 
Table 3  
UK pharmaceutical product registration fee comparison – decentralized vs. national registration 





National fee (including hybrid 
applications)  £ 92,753   £ 25,643   £ 9,402   £ 2,564  
Decentralised procedure where the UK is 
a concerned member state (CMS)  £ 89,556   £ 24,760   £ 9,078   £ 2,564  
Incoming mutual recognition with the UK 
as a CMS and European reference 
products 
 £ 62,421   £ 17,330   £ 6,350   £ 2,564  
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Decentralised procedure where UK is 
RMS  £ 121,664   £ 35,634   £ 15,659   £ 8,105  
Source: author’s construction based on (Medicines & Healthcare products Regulatory Agency, UK, 2019) 
Additionally this would exclude the option for UK to have a common/ joint packaging with other EU member 
states that require the products in English language (Ireland and Malta). As Ireland and Malta both have significantly 
smaller pharmaceutical markets in volume (compared with UK) the probability that pharmaceutical producers would 
decide to waive the registration of these pharmaceutical products in these member states increases.  
Nonetheless, as pharmaceutical products that have approved English packs are highly demanded in use outside 
English speaking countries (due to widespread use of English language worldwide) and the products that are approved 
via joint EU registration procedures are well received worldwide (due to high regulatory and quality standards in EU), 
after Brexit the pharmaceutical producers could be tempted to reconsider registration of their pharmaceutical products 
in the remaining English speaking EU member states (Ireland and Malta) despite the low pharmaceutical market 
volume in these countries.  
4.Possible supply issues of pharmaceutical products after Brexit 
The uncertainty that comes with the possible Brexit and the way how the negotiations between UK and EU have 
been progressing causes concerns within the pharmaceutical producers and distributors both in UK and EU.  
As reported by Marketline reports, in the situation of a no-deal Brexit the UK would lose preference in the EU 
markets, and the loss would amount to almost US$16bn, which is equivalent to approximately 7% of the overall 
exports to the EU, according to UNCTAD estimates that had taken into account only the increase in the tariffs. 
Moreover, border controls, disruption of production networks and the non-tariff barriers are expected to add to the 
losses (MarketLine, 2019). 
With respect to notes made by experts the pharmaceutical producers and distributors in EU and UK are currently 
facing with multiple difficulties and foresee possible pharmaceutical market development trends in post-Brexit 
scenario. 
UK pharmaceutical producer representative remarked that possible Brexit brings a huge damage to European 
trading environment, brings losses to UK economy, lowers the access to foreign markets and makes no economic 
sense whatsoever. It has also been noticed that some UK pharmaceutical producers have already transferred some of 
their marketing authorizations of pharmaceutical products to their EU based entities in order to remain part of the EU 
joint market and avoid possible negative consequences caused by Brexit. Such regulatory actions require extra 
financial and regulatory resources that could be invested elsewhere. Also, UK producers are stocking up their products 
in order to coupe with possible pharmaceutical product shortages that might come after Brexit takes place. As the 
Brexit date has been postponed already 3 times, the stocked up goods are seen as frozen assets that could be preferably 
used elsewhere, furthermore the shelf-life of the stocked goods is running, thus increasing the risk of product spoiling. 
Both exerts from UK pharmaceutical producers and distributors have noticed an increasing tendency of 
pharmaceutical product shortages in UK market. The increasing pharmaceutical product shortages could be explained 
by the lack of certainty what could happen after Brexit taking place and when could it actually happen (as it been 
already postponed multiple times). In some cases the pharmaceutical products in shortage are being replaced with 
other products and therefore patient therapies need to be adjusted accordingly. This further increases the consumption 
of replacing pharmaceutical products that eventually might result in further shortages as these pharmaceutical 
producers haven`t expected such increase in demand of their products.  
Furthermore, EU pharmaceutical producers noted that they are putting on hold their further investments into UK 
market (new research facilities, production sites, pharmaceutical product registrations, etc.) due to high uncertainty 
caused by possible Brexit.  
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So far both UK pharmaceutical producers and distributors experts haven`t noticed any major shifts in the workforce 
availability, still it is expected that there will be increasing demand for highly qualified personnel, especially in the 
pharmaceutical regulatory field as it is expected that MHRA will need extra experts to coupe with increasing numbers 
of pharmaceutical product National registration procedures and any producer that is expecting to register products in 
both EU and UK will need extra regulatory workforce to run both registrations in parallel. Nonetheless it has been 
observed that there has been a decrease in immigration in UK that can be explained by uncertainty caused by Brexit 
as potential immigrants from EU are not sure of their future within UK in case of a no deal Brexit. Also, as suggested 
by Marketline report of UK`s pharmaceutical industry in 2019, the UK`s research industry benefits significantly from 
European labor – life science PhD’s and Postdoctoral positions in particular. Thus, by Brexit taking place there`s a 
risk that it might cause damage to UK`s life science knowledge base (MarketLine, 2019). 
Both UK pharmaceutical producer and distributor experts indicated that at this stage it is hard to predict how Brexit 
could influence the competitiveness of UK pharmaceuticals producers as it only will be clear when a trade agreement 
between UK and EU would take place. Experts suggest that the uncertainty caused by multiple delays of Brexit and 
how it will take place causes more damage to the UK rather than potential Brexit itself. It is speculated that Brexit 
will bring loss to UK economy in a short term, but it`s hard to predict how it will effect UK in a long run. 
As noted by expert from UK pharmaceutical distributor the no deal Brexit would be the worst case scenario as 
there`s no “safety net” in this situation and lots of processes could be put on hold, especially logistics and movement 
of goods over EU-UK border. This could result in uncomfortable situation for Ireland as it is somewhat dependent on 
goods transit via UK and it brings doubts that Ireland logistic infrastructure could fully coupe with alternative logistic 
routes (direct air and sea transport from continental Europe) (BBC, 2018). 
 Furthermore, as noted by Ireland pharmaceutical distributor Ireland pharmaceutical market is much dependent 
on UK affairs as both countries commonly use unified packs for pharmaceutical products registered via same EU joint 
registration procedure and Ireland could usually be supplied with pharmaceutical products destined for UK market. 
Now if Brexit takes place and there will be separate registration procedures for Ireland and UK this option won`t be 
possible. Also, UK pharmaceutical companies are putting on hold their regulatory, business development and 
investment activities in Ireland due to uncertainties caused by possible Brexit. Furthermore, Ireland pharmaceutical 
distributors supplying pharmaceutical products from UK are faced with negative financial consequences caused by 
changes in exchange rates of British Pound and Euro that came after initiation of Brexit discussions. 
Irish pharmaceutical companies that are willing to develop business in UK now are forced to proceed with extra 
caution as UK economic is unpredictable due to uncertainties caused by potential Brexit. 
Pharmaceutical distributors in Ireland have been preparing for initial Brexit term and possible pharmaceutical 
product shortages that might come by filling in their stock with extra quantities of the products, but as the Brexit was 
postponed the products are now stacked in warehouses with shelf-life slowly expiring; the companies have made 
useless investments and have frozen their assets that could be used elsewhere. 
As suggested by experts, Ireland pharmaceutical distributors are tending to look for supplies of pharmaceutical 
products from other EU countries in order to reduce their dependency on UK producers. Suppliers that can deliver the 
products via air or sea route are preferred as in such case they can avoid the possibility that products will have to be 
shipped via UK where the movement of goods would be slowed down by customs and logistic costs increased due to 
possible tariffs. 
It is expected by experts of Ireland pharmaceutical industry that HPRA will adjust to pharmaceutical market 
situation caused by Brexit and will be more flexible on requirements for pharmaceutical product packages so they can 
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be combined with other EU markets (dual language packs) thus increasing interest for pharmaceutical producers to 
register and supply products to Ireland. 
Conclusions, proposals, recommendations 
1. The uncertainty and confusion caused by potential Brexit and multiple delays of it taking place has made an impact 
on UK`s economic growth that has slowed down to an average of 1.67% during 2016–2018. UK`s pharmaceutical 
market experienced a decline by 7% in Year 2016 and have returned to its previous value in Year 2018. 
2. Since 2016 Brexit has had a significant effect on investments in pharmaceutical industry caused by legislative and 
regulatory uncertainty – the pharmaceutical industry has become precautions to further investments in UK. Further 
investments in the industry could be expected when the Brexit actually takes place and it will be certain of how 
UK`s trade relationships with EU will be handled. 
3. After initiating the discussions of possible Brexit there has been confusion and uncertainties on how the 
pharmaceutical product registration will be processed in UK. Pharmaceutical companies willing to register their 
products in UK will have to align their regulatory strategy and apply for UK National registration (instead of using 
EU joint registration procedures). It is expected that pharmaceutical product registration timelines in UK will 
naturally increase and cause additional burden to both pharmaceutical industry and MHRA. 
4. Pharmaceutical companies that are willing to have their pharmaceutical products registered in EU with approved 
English pack will no longer have the option to register the products in UK via joint European registration 
procedures. EU pharmaceutical companies should reassess their marketing strategies and consider registering their 
products in Ireland and/ or Malta as an alternative, thus also increasing the variety of pharmaceutical products 
available in these EU markets. 
5. Although no issues with workforce availability in pharmaceutical field has been noticed so far, it is expected that 
after Brexit takes place there will be increased demand in regulatory experts in both private and public field. 
Additionally, it is expected that immigration of highly educated specialists from EU will decline, thus lowering 
the potential scientific capacity of UK`s pharmaceutical research industry. While EU pharmaceutical companies 
could take advantage of this situation and encourage these specialists to stay/ return in EU and contribute to 
development of EU pharmaceutical industry. 
6. Possible Brexit and multiple delays of it taking place have caused increased supply issues of pharmaceutical 
products in UK. This brings opportunities for pharmaceutical companies that are flexible enough to align their 
marketing strategies to complex and unpredictable UK`s pharmaceutical market. 
7. It is concluded that uncertainty caused by multiple delays of Brexit and how it will take place causes more damage 
to the UK rather than potential Brexit itself. It is suggested that politicians resolve the issue at the earliest 
convenience so pharmaceutical companies can proceed with developing long term marketing strategies to align 
with UK`s post-Brexit pharmaceutical market. 
8. Further observations and studies are recommended to be conducted on the EU and UK`s pharmaceutical market 
and industry after the Brexit takes place in order to evaluate the effect it has actually conducted on these fields. 
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